Formosanin C
Based on 5 publication(s) in Google Scholar
Formosanin C is a diosgenin saponin with multiple biological activities. Formosanin C possesses multiple anti-tumor mechanisms, including inducing apoptosis and autophagy, blocking the cell cycle, inhibiting metastasis and inducing ferroptosis. Formosanin C can inhibit the NF-κB signaling pathway to exert anti-inflammatory effects, and enhance the activity of immune cells. Formosanin C exhibits the inhibiting effect against C. albicans. Formosanin C can be used for the study of anti-inflammation, antifungal anti and anti-cancer (including lung cancer, liver cancer, breast cancer and colorectal cancer, etc.).
For research use only. We do not sell to patients.
- Purity : 99.28%
- CAS No.: 50773-42-7
- Formula: C51H82O20
- Molecular Weight:1015.18
-
Storage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Formosanin C
More-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
-
IF
-
WB
-
Apoptosis Analysis
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Bel-7402 | IC50 |
4.36 μM
Compound: FC
|
Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay
|
[PMID: 27623551] |
| HEK-293T | IC50 |
1.83 μM
Compound: 23
|
Cytotoxicity against human 293T cells assessed as reduction in cell viability after 72 hrs by MTS assay
Cytotoxicity against human 293T cells assessed as reduction in cell viability after 72 hrs by MTS assay
|
[PMID: 33310292] |
| HepG2 | IC50 |
3.76 μM
Compound: FC
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 27623551] |
| HUVEC | IC50 |
1.83 μM
Compound: 23
|
Cytotoxicity against HUVEC assessed as reduction in cell viability after 72 hrs by MTS assay
Cytotoxicity against HUVEC assessed as reduction in cell viability after 72 hrs by MTS assay
|
[PMID: 33310292] |
In Vitro
Formosanin C (0-10 μM, 0-4 days) significantly enhances the proliferation response of GM-CFCs in human peripheral whole blood to PHA (Phytohemagglutinin) (HY-11107), and in mouse lymphocytes to Concanavalin A (HY-P2149), as well as in mouse granulocyte/macrophage progenitor cells[1].
.
Formosanin C (24-72 h) inhibits HepG2, A549 and SW480 cells growth with IC50s of 13.62 μg/mL, 4.2 μM and 0.06 μM in 24 h, respectively[2][3].
.
Formosanin C (5-10 μg/mL, 24-48 h) induces apoptosis of HepG2 cells in a concentration- and time-dependent manner[2].
.
Formosanin C (0-8 μM, 24 h) suppresses the lung cancer A549 cells population through caspase activation-mediated apoptosis[3].
Formosanin C (0-5 μg/mL, 24 h) interferes with the cell cycle process by blocking HepG2 cells at the S phase[2].
.
Formosanin C (4 μM, 0-72 h) can induce early stage autophagy progression, proceed to blockage of autophagic flux in A549 cells, increase mitochondrial membrane potential, block autophagy progression, and has no influence on CCCP (HY-100941)-induced mitophagy[3].
Formosanin C (2-4 μM, 24 h) suppresses the motility of lung cancer cells through EMT (Epithelial-Mesenchymal Transition) pathway[3].
Formosanin C (5 μM, 24 h) induces ferritinophagy and ferroptosis via a lipid ROS-dependent processin liver cancer HepG2 cells[4].
Formosanin C (0.625-5 μM, 24 h) blunts LPS (HY-D1056)-induced NO and PGE production in a dose-dependent manner, inhibits iNOS and COX-2 expression, and blocks LPS-upregulated mRNA expression and medium release of TNF-α, IL-1β, and IL-6 in macrophages[5].
Formosanin C exhibits the inhibiting effect against C. albicans (MlC =1 ug/mL, pH = 7) and inhibits biofilm formation (MlC = 25 ug/mL)[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HepG2 cells
-
Concentration:5 and 10 μg/mL
-
Incubation Time:24 and 48 h
-
Result:Observed karyorrhexis and karyopyknosis.
The nucleuses were broken into pieces at 48 h.
Observed a signal DNA ladder for advanced stage apoptosis and fragmentation for 48 h.
-
Cell Line:HepG2 cells
-
Concentration:0, 1, 3 and 5 μg/mL
-
Incubation Time:24 h
-
Result:Resulted in a significant increase in the S phase and a decrease in the G2/M phase.
-
Cell Line:A549 cells
-
Concentration:2 and 4 μM
-
Incubation Time:24 h
-
Result:Showed 71% suppression of cell migration at 4 μM.
Decreased the levels of N-cadherin and vimentin.
-
Cell Line:macrophages
-
Concentration:0.625, 1.25, 2.5 and 5 μg/mL
-
Incubation Time:24 h
-
Result:Exhibited dose-dependent inhibition of iNOS and COX-2 protein expression.
Reduced the phosphorylation levels of IKK, IκBα and p65.
Did not affect the total protein expression of IKK, IκBα and p65.
-
Cell Line:macrophages
-
Concentration:0.625, 1.25, 2.5 and 5 μg/mL
-
Incubation Time:24 h
-
Result:Significantly inhibited the expression of iNOS and COX-2 mRNA induced by LPS.
Dose-dependently reduced the mRNA levels of TNF-α, IL-1β and IL-6.
In Vivo
Formosanin C (1-5 mg/kg, i.p., once daily for 11 days or every other day for 13 days) significantly inhibited tumor growth in MH-134 cells induced mice xenograft model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MH-134 hepatoma xenograft model established in C3H/HeN mice (male, 8 weeks old)[1]
-
Dosage:1, 2.5 and 5 mg/kg
-
Administration:Intraperitoneal injection (i.p.), once daily for 11 days or every other day for 13 days
-
Result:Significantly inhibited tumor growth, with 2.5 mg/kg dose of the most effective.
Alleviated the toxicity caused by the high dose with alternate-day administration.
Chemical Information
-
CAS No. 50773-42-7
-
Appearance Solid
-
Molecular Weight 1015.18
-
Formula C51H82O20
-
Color White to off-white
-
SMILES
C[C@@]12[C@]3([H])[C@](O[C@]4(CC[C@@H](C)CO4)[C@H]3C)([H])C[C@@]1([H])[C@@]5([H])[C@]([C@@]6(C(C[C@@H](O[C@@]7([H])[C@@H]([C@H]([C@H](O[C@@]8([H])[C@@H]([C@@H]([C@@H](O[C@@]9([H])[C@@H]([C@@H]([C@@H](O)[C@H](C)O9)O)O)[C@H](C)O8)O)O)[C@@H](CO)O7)O)O[C@@]%10([H])[C@@H]([C@@H]([C@@H](O)[C@H](C)O%10)O)O)CC6)=CC5)C)([H])CC2
-
Structure Classification
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
Formosanin C induces autophagy-mediated cell death in hepatocellular carcinoma through activating DUSP1/AMPK/ULK1/Beclin1 signaling pathway. [Abstract]2025 Mar:138:156404. PMID: 39862789
Formosanin C purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Mar:138:156404. [Abstract]
Cell viability measured by CCK-8. Cells were incubated with various concentrations of FC (0, 1.25, 2.5, 5, 10, 20 μM) for 24 h.
Formosanin C purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Mar:138:156404. [Abstract]
Clone formation. Cells were treated with FC for 4 days treated with Formosanin C (FC) (0, 4, 8 μM).
Formosanin C purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Mar:138:156404. [Abstract]
EdU determination for cell proliferation treated with Formosanin C (FC) (0, 4, 8 μM).
Formosanin C purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Mar:138:156404. [Abstract]
Western blot analysis for Ki67, CyclinB1, CDK1, p27 and γ-H2AX treated with Formosanin C (FC) (0, 4, 8 μM).
Formosanin C purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Mar:138:156404. [Abstract]
Flow cytometric detection of apoptosis treated with Formosanin C (FC) (0, 4, 8 μM).
Formosanin C purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Mar:138:156404. [Abstract]
Migration rate was expressed as ratio of migration distance to total distance of the wound gap treated with Formosanin C (FC) (0, 4, 8 μM).
-
Phytother Res
Formosanin C Induces ROS/p38-Mediated Cell Death While Also Promoting Protective Autophagy in Pancreatic Cancer. [Abstract]2025 Oct 6. PMID: 41054182 -
Breast Cancer Res Treat
Formosanin C inhibits triple-negative breast cancer progression by suppressing the phosphorylation of STAT3 and the polarization of M2 macrophages. [Abstract]2025 May;211(1):71-89. PMID: 39953272 -
Korean J Physiol Pharmacol
Formosanin C attenuates lipopolysaccharide-induced inflammation through nuclear factor-κB inhibition in macrophages. [Abstract]2021 Sep 1;25(5):395-401. PMID: 34448457 -
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (98.50 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.46 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
-
Data Sheet (298 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wu RT, et al. Formosanin-C, an immunomodulator with antitumor activity. Int J Immunopharmacol. 1990;12(7):777-86. [Content Brief]
[2]. Li Y, et al. The antitumor effect of formosanin C on HepG2 cell as revealed by 1H-NMR based metabolic profiling. Chem Biol Interact. 2014 Sep 5;220:193-9. [Content Brief]
[3]. Chu ML, et al. Formosanin C suppresses cancer cell proliferation and migration by impeding autophagy machinery. Kaohsiung J Med Sci. 2023 May;39(5):489-500. [Content Brief]
[4]. Lin PL, et al. Saponin Formosanin C-induced Ferritinophagy and Ferroptosis in Human Hepatocellular Carcinoma Cells. Antioxidants (Basel). 2020 Jul 29;9(8):682. [Content Brief]
[5]. Yin L, et al. Formosanin C attenuates lipopolysaccharide-induced inflammation through nuclear factor-κB inhibition in macrophages. Korean J Physiol Pharmacol. 2021 Sep 1;25(5):395-401. [Content Brief]
[6]. Dorsaz S, et al. Identification and Mode of Action of a Plant Natural Product Targeting Human Fungal Pathogens. Antimicrob Agents Chemother. 2017 Aug 24;61(9):e00829-17. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.9850 mL | 4.9252 mL | 9.8505 mL | 24.6262 mL |
| 5 mM | 0.1970 mL | 0.9850 mL | 1.9701 mL | 4.9252 mL | |
| 10 mM | 0.0985 mL | 0.4925 mL | 0.9850 mL | 2.4626 mL | |
| 15 mM | 0.0657 mL | 0.3283 mL | 0.6567 mL | 1.6417 mL | |
| 20 mM | 0.0493 mL | 0.2463 mL | 0.4925 mL | 1.2313 mL | |
| 25 mM | 0.0394 mL | 0.1970 mL | 0.3940 mL | 0.9850 mL | |
| 30 mM | 0.0328 mL | 0.1642 mL | 0.3283 mL | 0.8209 mL | |
| 40 mM | 0.0246 mL | 0.1231 mL | 0.2463 mL | 0.6157 mL | |
| 50 mM | 0.0197 mL | 0.0985 mL | 0.1970 mL | 0.4925 mL | |
| 60 mM | 0.0164 mL | 0.0821 mL | 0.1642 mL | 0.4104 mL | |
| 80 mM | 0.0123 mL | 0.0616 mL | 0.1231 mL | 0.3078 mL |